Voyager Therapeutics

VYGRNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$105.983 M

$1.72 -8.02%

Close of 6 Nov 2026

As of 6 Nov 2026, Voyager Therapeutics (VYGR) has a market capitalization of $106.0M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$40.4M

#2783 by revenue

Earnings

-$119.7M

Loss-making

Shares outstanding

62,229,182

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#109HumacyteHUMA$108.3M
#110Outlook TherapeuticsOTLK$107.3M
#111Voyager TherapeuticsVYGR$106.0M
#112Anavex Life SciencesAVXL$102.4M
#113Black Diamond TherapeuticsBDTX$95.7M

What if Voyager Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$458,257.29

Per share 266,429× higher

Bitcoin $1.53T

$24,795.50

Per share 14,416× higher

Apple $5.02T

$81,401.32

Per share 47,326× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Voyager Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.